Trial Profile

Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; Therapeutic Use
Acronyms STAR
Sponsors Bayer

Most Recent Events

08 Jul 2009 Actual patient number (6) added as reported by ClinicalTrials.gov.
08 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
16 Jun 2009 Planned end date changed from Oct 2009 to Jun 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com